Recent treatment modalities for cardiovascular diseases with a focus on stem cells, aptamers, exosomes and nanomedicine

References

• de Mestral C, Stringhini S. Socioeconomic status and cardiovascular disease: an update. Curr Cardiol Rep. 2017;19:115.
   PubMed Web of Science ®Google Scholar
• Kwan GF, Mayosi BM, Mocumbi AO, et al. Endemic cardiovascular diseases of the poorest billion. Circulation. 2016;133:2561–2575.
   PubMed Web of Science ®Google Scholar
• Karjalainen PP, Nammas W. Percutaneous revascularization of coronary chronic total occlusion: toward a reappraisal of the available evidence. J Cardiol. 2017;69:799–807.
   PubMed Web of Science ®Google Scholar
• Nammas W, Pietila M, Romppanen H, et al. Outcome of poor initial TIMI flow in patients presenting with acute coronary syndrome. Scand Cardiovasc J. 2017;51:248–254.
   PubMed Web of Science ®Google Scholar
• Quyyumi AA, Vasquez A, Kereiakes DJ, et al. PreSERVE-AMI: a randomized, double-blind, placebo-controlled clinical trial of intracoronary administration of autologous CD34+ cells in patients with left ventricular dysfunction post STEMI. Circ Res. 2017;120:324–331.
   PubMed Web of Science ®Google Scholar
• Traverse JH, Henry TD, Pepine CJ, et al. The TIME trial - effect of timing of stem cell delivery following st-elevation myocardial infarction on the recovery of global and regional left ventricular function: final 2-year analysis. Circ Res. 2018;122:479–488.
   PubMed Web of Science ®Google Scholar
• Perin EC. Stem cell therapy for cardiovascular disease. Tex Heart Inst J. 2006;33:204.
   PubMed Web of Science ®Google Scholar
• Pelacho B, Nakamura Y, Zhang J, et al. Multipotent adult progenitor cell transplantation increases vascularity and improves left ventricular function after myocardial infarction. J Tissue Eng Regen Med. 2007;1:51–59.
   PubMed Web of Science ®Google Scholar
• Ghostine S, Carrion C, Souza LC, et al. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation. 2002;106:I131–I136.
   PubMed Web of Science ®Google Scholar
• Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167:989–997.
   PubMed Web of Science ®Google Scholar
• Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010;12:721–729.
   PubMed Web of Science ®Google Scholar
• Schachinger V, Erbs S, Elsasser A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27:2775–2783.
   PubMed Web of Science ®Google Scholar
• Meluzin J, Janousek S, Mayer J, et al. Three-, 6-, and 12-month results of autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction. Int J Cardiol. 2008;128:185–192.
   PubMed Web of Science ®Google Scholar
• Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (cardiopoietic stem cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61:2329–2338.
   PubMed Web of Science ®Google Scholar
• Hare JM, Chaparro SV. Cardiac regeneration and stem cell therapy. Curr Opin Organ Transplant. 2008;13:536.
   PubMed Web of Science ®Google Scholar
• Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4:214–222.
   PubMed Web of Science ®Google Scholar
• Tomita S, Li RK, Weisel RD, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation. 1999;100:II247–II256.
   PubMed Web of Science ®Google Scholar
• El Sayed Shafei A, Ali MA, Ghanem HG, et al. Mesenchymal stem cells therapy: a promising cell based therapy for treatment of myocardial infarction. J Gene Med. 2017;19:e2995.
   Web of Science ®Google Scholar
• Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763–776.
   PubMed Web of Science ®Google Scholar
• Ranganath SH, Levy O, Inamdar MS, et al. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012;10:244–258.
   PubMed Web of Science ®Google Scholar
• Laugwitz KL, Moretti A, Lam J, et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005;433:647–653.
   PubMed Web of Science ®Google Scholar
• Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA. 2003;100:12313–12318.
   PubMed Web of Science ®Google Scholar
• Takemiya K, Kai H, Yasukawa H, et al. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol. 2010;105:409–417.
   PubMed Web of Science ®Google Scholar
• Hansmann G, Fernandez-Gonzalez A, Aslam M, et al. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ. 2012;2:170–181.
   PubMedGoogle Scholar
• Umar S, de Visser YP, Steendijk P, et al. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009;297:H1606–H1616.
   PubMed Web of Science ®Google Scholar
• Mirotsou M, Jayawardena TM, Schmeckpeper J, et al. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol. 2011;50:280–289.
   PubMed Web of Science ®Google Scholar
• Karp JM, Teo GSL. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4:206–216.
   PubMed Web of Science ®Google Scholar
• Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109:923–940.
   PubMed Web of Science ®Google Scholar
• Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008;451:937.
   PubMed Web of Science ®Google Scholar
• Lan F, Lee AS, Liang P, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12:101–113.
   PubMed Web of Science ®Google Scholar
• Zhang YM, Hartzell C, Narlow M, et al. Stem cell-derived cardiomyocytes demonstrate arrhythmic potential. Circulation. 2002;106:1294–1299.
   PubMed Web of Science ®Google Scholar
• Navarrete EG, Liang P, Lan F, et al. Screening drug-induced arrhythmia using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation. 2013;128:S3–S13.
   PubMed Web of Science ®Google Scholar
• Li W, Wang K, Zhao M, et al. Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status. Thromb Res. 2014;134: 769–773.
   PubMed Web of Science ®Google Scholar
• Wang P, Yang Y, Hong H, et al. Aptamers as therapeutics in cardiovascular diseases. Curr Med Chem. 2011;18:4169–4174.
   PubMed Web of Science ®Google Scholar
• Hu PP, Zhang KH. The modulation of coagulation by aptamers: an up-to-date review. Blood Coagul Fibriolysis. 2015;26:1–6.
   PubMed Web of Science ®Google Scholar
• Port JD, Bristow MR. Aptamer therapy for heart failure? Circ Res. 2011;109:982–983.
   PubMed Web of Science ®Google Scholar
• Haberland A, Wallukat G, Dahmen C, et al. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res. 2011;109:986–992.
   PubMed Web of Science ®Google Scholar
• Sabatine MS. Using aptamer-based technology to probe the plasma proteome for cardiovascular disease prediction. JAMA. 2016;315:2525–2526.
   Web of Science ®Google Scholar
• Zhao W, Zheng XL, Zhao SP. Exosome and its roles in cardiovascular diseases. Heart Fail Rev. 2015;20:337–348.
   PubMed Web of Science ®Google Scholar
• Emanueli C, Shearn AI, Angelini GD, et al. Exosomes and exosomal miRNAs in cardiovascular protection and repair. Vascul Pharmacol. 2015;71:24–30.
   PubMed Web of Science ®Google Scholar
• Xu JY, Chen GH, Yang YJ. Exosomes: a rising star in falling hearts. Front Physiol. 2017;8:494.
   PubMed Web of Science ®Google Scholar
• Ratajczak J, Wysoczynski M, Hayek F, et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006;20:1487–1495.
   PubMed Web of Science ®Google Scholar
• Barile L, Lionetti V, Cervio E, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res. 2014;103:530–541.
   PubMed Web of Science ®Google Scholar
• Vicencio JM, Yellon DM, Sivaraman V, et al. Plasma exosomes protect the myocardium from ischemia-reperfusion injury. J Am Coll Cardiol. 2015;65:1525–1536.
   PubMed Web of Science ®Google Scholar
• Madonna R, Van Laake LW, Davidson SM, et al. Position paper of the European society of cardiology working group cellular biology of the heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J. 2016;37:1789–1798.
   PubMed Web of Science ®Google Scholar
• Davidson SM, Takov K, Yellon DM. Exosomes and cardiovascular protection. Cardiovasc Drugs Ther. 2017;31:77–86.
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia HM, Vaina S, Tsuchida K, et al. Drug-eluting stents. Arch Cardiol Mex. 2006;76:297–319.
   PubMedGoogle Scholar
• Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102:399–404.
   PubMed Web of Science ®Google Scholar
• Soehnlein O, Swirski FK. Hypercholesterolemia links hematopoiesis with atherosclerosis. Trends Endocrinol Metab. 2013;24:129–136.
   PubMed Web of Science ®Google Scholar
• Crowson CS, Liao KP, Davis JM, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013;166:622–628 e1.
   PubMed Web of Science ®Google Scholar
• Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010;49:295–307.
   PubMed Web of Science ®Google Scholar
• Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63:522–529.
   PubMed Web of Science ®Google Scholar
• Kraakman MJ, Dragoljevic D, Kammoun HL, et al. Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis. Clin Trans Immunol. 2016;5:e84.
   PubMed Web of Science ®Google Scholar
• Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014;53:2143–2154.
   PubMed Web of Science ®Google Scholar
• Chappell JC, Song J, Burke CW, et al. Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis. Small. 2008;4:1769–1777.
   PubMed Web of Science ®Google Scholar
• Kim J, Cao L, Shvartsman D, et al. Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett. 2011;11:694–700.
   PubMed Web of Science ®Google Scholar
• Raman R, Sasisekharan V, Sasisekharan R. Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem Biol. 2005;12:267–277.
   PubMed Web of Science ®Google Scholar
• Silva AK, Letourneur D, Chauvierre C. Polysaccharide nanosystems for future progress in cardiovascular pathologies. Theranostics. 2014;4:579–591.
   PubMed Web of Science ®Google Scholar
• Szymanska E, Winnicka K. Stability of chitosan-a challenge for pharmaceutical and biomedical applications. Mar Drugs. 2015;13:1819–1846.
   PubMed Web of Science ®Google Scholar
• Chung TW, Yang MC, Tsai WJ. A fibrin encapsulated liposomes-in-chitosan matrix (FLCM) for delivering water-soluble drugs. Influences of the surface properties of liposomes and the crosslinked fibrin network. Int J Pharm. 2006;311:122–129.
   PubMed Web of Science ®Google Scholar
• Chung TW, Wang SS, Tsai WJ. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles. Biomaterials. 2008;29:228–237.
   PubMed Web of Science ®Google Scholar
• Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res. 2011;44:842–852.
   PubMed Web of Science ®Google Scholar
• McCarthy JR, Sazonova IY, Erdem SS, et al. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy. Nanomedicine. 2012;7:1017–1028.
   PubMed Web of Science ®Google Scholar
• Bi F, Zhang J, Su Y, et al. Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. Biomaterials. 2009;30:5125–5130.
   PubMed Web of Science ®Google Scholar
• McCarthy JR, Korngold E, Weissleder R, et al. A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small. 2010;6:2041–2049.
   PubMed Web of Science ®Google Scholar
• Katsuki S, Matoba T, Nakashiro S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation. 2014;129:896–906.
   PubMed Web of Science ®Google Scholar
• Koga J, Matoba T, Egashira K. Anti-inflammatory nanoparticle for prevention of atherosclerotic vascular diseases. J Atheroscler Thromb. 2016;23:757–765.
   PubMed Web of Science ®Google Scholar
• Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107:2453–2458.
   PubMed Web of Science ®Google Scholar
• Trivedi RA, U-King-Im JM, Graves MJ, et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke. 2004;35:1631–1635.
   PubMed Web of Science ®Google Scholar
• Kang C, Gwon S, Song C, et al. Fibrin-targeted and H2O2-responsive nanoparticles as a theranostics for thrombosed vessels. ACS Nano. 2017;11:6194–6203.
   PubMed Web of Science ®Google Scholar
• Huang Z, Song Y, Pang Z, et al. Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles. Int J Nanomedicine. 2017;12:3023–3036.
   PubMed Web of Science ®Google Scholar
• Nagaoka K, Matoba T, Mao Y, et al. A new therapeutic modality for acute myocardial infarction: nanoparticle-mediated delivery of pitavastatin induces cardioprotection from ischemia-reperfusion injury via activation of PI3K/Akt pathway and anti-inflammation in a rat model. PLoS One. 2015;10:e0132451.
   PubMed Web of Science ®Google Scholar
• Yin RX, Yang DZ, Wu JZ. Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics. 2014;4:175–200.
   PubMed Web of Science ®Google Scholar
• Lian L, Tang F, Yang J, et al. Therapeutic angiogenesis of PLGA-Heparin Nanoparticle in mouse ischemic limb. J Nanomaterials. 2012;2012:193704.
   Web of Science ®Google Scholar
• Xie J, Wang H, Wang Y, et al. Induction of angiogenesis by controlled delivery of vascular endothelial growth factor using nanoparticles. Cardiovasc Ther. 2013;31:e12–e18.
   PubMed Web of Science ®Google Scholar
• Chang MY, Yang YJ, Chang CH, et al. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J Control Release. 2013;170:287–294.
   PubMed Web of Science ®Google Scholar
• Gray WD, Che P, Brown M, et al. N-acetylglucosamine conjugated to nanoparticles enhances myocyte uptake and improves delivery of a small molecule p38 inhibitor for post-infarct healing. J Cardiovasc Transl Res. 2011;4:631–643.
   PubMed Web of Science ®Google Scholar
• Somasuntharam I, Boopathy AV, Khan RS, et al. Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials. 2013;34:7790–7798.
   PubMed Web of Science ®Google Scholar
• Smalling RW, Feld S, Ramanna N, et al. Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model. Circulation. 1995;92:935–943.
   PubMed Web of Science ®Google Scholar
• Verma DD, Hartner WC, Levchenko TS, et al. ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res. 2005;22:2115–2120.
   PubMed Web of Science ®Google Scholar
• Scott RC, Rosano JM, Ivanov Z, et al. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 2009;23:3361–3367.
   PubMed Web of Science ®Google Scholar